X4 Pharmaceuticals (XFOR) Stifel 2024 Healthcare Conference summary

Key product and commercial updates

• Achieved FDA approval for mavorixafor (XOLREMDI) in April and met initial launch metrics, focusing on physician education and awareness in the first half of the year.

• All patients from the Phase 3 and open-label extension trials have converted to commercial therapy, with reimbursement processes ongoing and expected to contribute to revenue growth in 2025 and beyond.

• Physician outreach has reached over 3,000 targeted HCPs, with more than 75% now aware of WHIM syndrome and prepared to prescribe XOLREMDI.

• Commercial efforts include peer-to-peer webinars and nurse educator programs to drive patient identification and engagement.

• Payer coverage now extends to about 150 million lives, with reimbursement cycle times averaging 90 days and expected to tighten as experience grows.

Market dynamics and patient onboarding

• WHIM is characterized as an ultra-orphan market with gradual patient onboarding, as there was no large pool of patients awaiting treatment at launch.

• Demand, education, and screening are increasing, with known patient-physician pairs expected to convert more readily in 2025.

• No significant barriers have been observed in patient willingness to initiate therapy, and the payer mix is predominantly commercial due to the younger patient population.

• The majority of patients are above the 50 kg threshold, aligning with Phase 3 trial demographics and pricing assumptions.

Strategic and international expansion

• Plans are on track to file an MAA in early 2025, with potential partnerships under consideration to expand ex-US presence.

• Significant strategic interest exists, with deal structures to be determined based on partner capabilities and value proposition.

• European market research suggests robust opportunity, with tertiary care systems aiding patient identification and a similar market size to the US on a population-adjusted basis.